Russell Investments Group Ltd. Acquires 72,240 Shares of Aurinia Pharmaceuticals Inc $AUPH

Russell Investments Group Ltd. grew its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 1,289.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,843 shares of the biotechnology company’s stock after purchasing an additional 72,240 shares during the quarter. Russell Investments Group Ltd. owned about 0.06% of Aurinia Pharmaceuticals worth $626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Nuveen LLC bought a new stake in Aurinia Pharmaceuticals in the first quarter worth approximately $10,014,000. Tang Capital Management LLC grew its position in shares of Aurinia Pharmaceuticals by 16.6% during the 4th quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock worth $75,697,000 after buying an additional 1,200,000 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $7,630,000. Jupiter Asset Management Ltd. acquired a new position in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $6,052,000. Finally, Lazard Asset Management LLC lifted its position in shares of Aurinia Pharmaceuticals by 341.9% during the 4th quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company’s stock valued at $5,355,000 after acquiring an additional 461,430 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Insiders Place Their Bets

In related news, Director Kevin Tang purchased 1,000,000 shares of the business’s stock in a transaction on Friday, August 1st. The stock was acquired at an average price of $10.12 per share, for a total transaction of $10,120,000.00. Following the purchase, the director owned 11,029,500 shares of the company’s stock, valued at approximately $111,618,540. This trade represents a 9.97% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have bought 1,300,000 shares of company stock valued at $13,590,000. 12.20% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock opened at $11.99 on Friday. The firm has a market capitalization of $1.58 billion, a PE ratio of 27.88 and a beta of 1.23. The firm has a fifty day simple moving average of $9.89 and a two-hundred day simple moving average of $8.68. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a 12 month low of $6.42 and a 12 month high of $12.53.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million during the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on AUPH shares. Royal Bank Of Canada raised their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.00.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.